A recent retrospective cohort study similarly showed that GLP-1R agonist use was associated with a lower risk of pancreatic cancer compared with use of several other antihyperglycemic drugs, including insulin, metformin, DPP4 inhibitors, SGLT2 inhibitors, sulfonylurea, or thiazolidinediones (TZDs) (53). Here, GLP1R is linked to familial pancreatic carcinoma.